Piper Sandler Maintains Overweight on GeneDx Holdings, Raises Price Target to $63
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsPrice Target
Piper Sandler analyst David Westenberg maintains GeneDx Holdings (NASDAQ:WGS) with a Overweight and raises the price target from $50 to $63.
Piper Sandler analyst David Westenberg maintains GeneDx Holdings (NASDAQ:WGS) with a Overweight and raises the price target from $50 to $63.